Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 9/20 | 0.58 |
| ▸ | IKZF3 | Q9UKT9 | 3/20 | 0.58 |
| ▸ | IKZF1 | Q13422 | 3/20 | 0.58 |
| ▸ | TNF | P01375 | 3/20 | 0.58 |
| ▸ | IL1B | P01584 | 3/20 | 0.58 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.58 |
| ▸ | BRD4 | O60885 | 1/20 | 0.58 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | PARP1 | P09874 | 1/20 | 0.35 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.33 |
| ▸ | MAP1LC3B | Q9GZQ8 | 5/20 | 0.32 |
| ▸ | CDK4 | P11802 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12132418 | 1.00 | CRBN (0.58) | CRBNIKZF3IKZF1TNFIL1B | |
| SCHEMBL12132387 | 1.00 | CRBN (0.58) | CRBNIKZF3IKZF1TNFIL1B | |
| SCHEMBL12132401 | 0.90 | CRBN (0.54) | CRBNIKZF3IKZF1TNFIL1B | |
| SCHEMBL12132382 | 0.90 | CRBN (0.54) | CRBNIKZF3IKZF1TNFIL1B | |
| SCHEMBL12132403 | 0.90 | CRBN (0.54) | CRBNIKZF3IKZF1TNFIL1B | |
| Lenalidomide SCHEMBL12132415 | 0.88 | CRBN (0.74) | CRBNIKZF3IKZF1TNFIL1B | |
| SCHEMBL677652 | 0.86 | CRBN (0.78) | CRBNIKZF3IKZF1TNFIL1B | |
| SCHEMBL17246851 | 0.86 | CRBN (0.78) | CRBNIKZF3IKZF1TNFIL1B | |
| SCHEMBL12132397 | 0.85 | CRBN (0.51) | CRBNIKZF3IKZF1TNFIL1B | |
| SCHEMBL12132391 | 0.85 | CRBN (0.51) | CRBNIKZF3IKZF1TNFIL1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110288126-A1 | SUBSTITUTED DIOXOPIPERIDINYL PHTHALIMIDE DERIVATIVES | CONCERT PHARMACEUTICALS, INC. (US) | 2011-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110288126-A1 | SUBSTITUTED DIOXOPIPERIDINYL PHTHALIMIDE DERIVATIVES | NFATC1, PDCD11, IL5 | CRBN 2182/4885IKZF3 126/4885IKZF1 146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.